Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer

Inclusion Criteria:

* Histologically or cytologically diagnosed advanced or metastatic malignancy that is refractory to, not curable with, or not eligible for standard treatment(s).
* 18 years or older
* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
* Resolution of any toxic effects of prior therapy (except alopecia) to National Cancer Institute Common Terminology Criteria for Adverse Events v3.0 grade less than or equal to 1.
* Adequate organ and bone marrow function.
* Willing to use effective contraceptive while on treatment through at least 3 months thereafter.
* Negative pregnancy test for females of childbearing potential.
* Echocardiogram with ejection fraction within normal range.

Exclusion Criteria:

* Anticipation of need for a major surgical procedure or radiation therapy during the study.
* Treatment with chemotherapy, hormonal therapy, other thiazolidinediones, radiotherapy, minor surgery, or any investigational agent within 4 weeks (6 weeks for nitrosoureas, mitomycin C, immunotherapy, biological therapy, or major surgery) of study treatment start.
* Participants with clinically significant pleural or pericardial effusion (participants with minimal pleural effusion may be eligible at the Investigator's discretion).
* Clinically significant active infection, which requires antibiotic therapy, or human immunodeficiency virus (HIV)-positive participants receiving antiretroviral therapy.